SMC Approves Alimera’s Iluvien for NHS Scotland
Alimera Sciences yesterday announced that the Scottish Medicines Consortium (SMC) has approved Iluvien as a treatment for chronic diabetic macular oedema (DME) for restricted use within the NHS in the country.
Use of Iluvien will be restricted to patients in whom the affected eye is pseudophakic, meaning that they have an artificial lens after cataract surgery.
The advice issued by the Scottish Medicines Consortium provides NHS Scotland patients considered insufficiently responsive to available therapies with access to Iluvien, the only sustained-release treatment for chronic diabetic macular edema.
In addition, retreatment with Iluvien is predicated on a positive response to, and subsequent need for the product.
William Wykes, consultant ophthalmologist at National Health Service (NHS) Southern General Hospital, commented that the SMC regulatory acceptance “is wonderful news for DME patients in Scotland,” adding that “vision is so important to a person’s overall quality of life.” The SMC advice follows positive NICE final regulatory guidance, which was issued in November 2013.